Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches

Drug Resistance Updates

Volumn 13, Issue 3, 2010, Pages 67-78

  Lai, Stephen Y ^a   Johnson, Faye M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

EGFR; Head and neck cancer; IL 6; JAK; Lung cancer; Signaling pathways; STAT

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ANTINEOPLASTIC AGENT; AZD 1480; BUNGAROTOXIN RECEPTOR; CISPLATIN; CPA 1; CPA 7; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROPOIETIN RECEPTOR; GALIELLALACTONE; INTERLEUKIN RECEPTOR; IS 3295; JANUS KINASE; JANUS KINASE INHIBITOR; LS 104; NSC 74859; PEPTIDE APTAMER; PROTEIN KINASE P60; PYRIDONE 6; PYRIDONE DERIVATIVE; SB 1518; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 019;

ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANGIOGENESIS; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DIMERIZATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; LEUKEMIA; LEUKOPENIA; LIGAND BINDING; LUNG CANCER; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEGATIVE FEEDBACK; NEUROTOXICITY; NONHUMAN; PLEIOTROPY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; LUNG NEOPLASMS; MICE; OLIGONUCLEOTIDES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 77953019852     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.04.001     Document Type: Article

References (132)

1. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., and Frank D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 66 (2006) 3162-3168
2. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., Kim Y.H., Pollack J.R., Yanagisawa K., Gazdar A., Minna J.D., Kurie J.M., and Carbone D.P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 1 (2005) 226-235
3. Apostolidou E., Kantarjian H.M., and Verstovsek S. JAK2 inhibitors: a reality? A hope?. Clin. Lymphoma Myeloma 9 Suppl. 3 (2009) S340-345
4. Arredondo J., Chernyavsky A.I., Jolkovsky D.L., Pinkerton K.E., and Grando S.A. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J. 20 (2006) 2093-2101
5. Barton B.E., Murphy T.F., Shu P., Huang H.F., Meyenhofer M., and Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther. 3 (2004) 1183-1191
6. Becker S., Groner B., and Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394 (1998) 145-151
7. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., Barnato S.E., Elverman K.M., Courtney D.M., McKoy J.M., Edwards B.J., Tigue C.C., Raisch D.W., Yarnold P.R., Dorr D.A., Kuzel T.M., Tallman M.S., Trifilio S.M., West D.P., Lai S.Y., and Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
8. Bezzerri V., Borgatti M., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., Rizzotti P., Gambari R., and Cabrini G. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am. J. Respir. Cell. Mol. Biol. 39 (2008) 86-96
9. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
10. Buerger C., Nagel-Wolfrum K., Kunz C., Wittig I., Butz K., Hoppe-Seyler F., and Groner B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem. 278 (2003) 37610-37621
11. Byers L.A., Sen B., Saigal B., Diao L., Wang J., Nanjundan M., Cascone T., Mills G.B., Heymach J.V., and Johnson F.M. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin. Cancer Res. (2009)
12. Chatti K., Farrar W.L., and Duhe R.J. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43 (2004) 4272-4283
13. Chen C.L., Loy A., Cen L., Chan C., Hsieh F.C., Cheng G., Wu B., Qualman S.J., Kunisada K., Yamauchi-Takihara K., and Lin J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7 (2007) p111
14. Coppo P., Flamant S., De Mas V., Jarrier P., Guillier M., Bonnet M.L., Lacout C., Guilhot F., Vainchenker W., and Turhan A.G. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol. 134 (2006) 171-179
15. Cortas T., Eisenberg R., Fu P., Kern J., Patrick L., and Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 55 (2007) 349-355
16. Dalwadi H., Krysan K., Heuze-Vourc'h N., Dohadwala M., Elashoff D., Sharma S., Cacalano N., Lichtenstein A., and Dubinett S. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 7674-7682
17. Dent P., Curiel D.T., Fisher P.B., and Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist. Update 12 (2009) 65-73
18. Ferrajoli A., Faderl S., Van Q., Koch P., Harris D., Liu Z., Hazan-Halevy I., Wang Y., Kantarjian H.M., Priebe W., and Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 67 (2007) 11291-11299
19. Fridman J., Nussenzveig R., Liu P., Rodgers J., Burn T., Haley P., Scherle P., Newton R., Hollis G., Friedman S., Verstovsek S., and Vaddi K. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood (Am. Soc. Hematol. Annu. Meeting Abstracts) 110 (2007) (abstract 3538)
20. Fu X.Y., and Zhang J.J. Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74 6 (1993) 1135-1145
21. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., and Bromberg J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117 (2007) 3846-3856
22. Giles F., Bergstrom D.A., Garcia-Manero G., Kornblau S., Andreeff M., Kantarjian H., Jones D., Freedman S.J., and Verstovsek S. MK-0457 is a novel Aurora kinase and Janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). ASH Annu. Meeting Abstracts 108 (2006) 4893
23. Gollamudi M., Nethery D., Liu J., and Kern J.A. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer 43 (2004) 135-143
24. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., and Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324 (2009) 1713-1716
25. Gozgit J.M., Bebernitz G., Patil P., Ye M., Parmentier J., Wu J., Su N., Wang T., Ioannidis S., Davies A., Huszar D., and Zinda M. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J. Biol. Chem. 283 (2008) 32334-32343
26. Grandage V.L., Everington T., Linch D.C., and Khwaja A. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br. J. Haematol. 135 (2006) 303-316
27. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., and Tweardy D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. 102 (1998) 1385-1392
28. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., Johnson D.E., Huang L., He Y., and Kim J.D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4227-4232
29. Gray M.J., Zhang J., Ellis L.M., Semenza G.L., Evans D.B., Watowich S.S., and Gallick G.E. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24 19 (2005) 3110-3120
30. Greenhalgh C.J., and Alexander W.S. Suppressors of cytokine signalling and regulation of growth hormone action. Growth Horm. IGF Res. 14 3 (2004) 200-206
31. Grunberger T., Demin P., Rounova O., Sharfe N., Cimpean L., Dadi H., Freywald A., Estrov Z., and Roifman C.M. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood 102 (2003) 4153-4158
32. Han Y., Amin H.M., Franko B., Frantz C., Shi X., and Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108 (2006) 2796-2803
33. Hao W., Hu Y., Niu C., Huang X., Chang C.P., Gibbons J., and Xu J. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg. Med. Chem. Lett. 18 (2008) 4988-4992
34. Haura E.B., Zheng Z., Song L., Cantor A., and Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 8288-8294
35. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., Costello J.F., McCormick F., and Jablons D.M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 14133-14138
36. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., and Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16 (2009) 487-497
37. Henderson Y.C., Guo X.Y., Greenberger J., and Deisseroth A.B. Potential role of bcr-abl in the activation of JAK1 kinase. Clin. Cancer Res. 3 (1997) 145-149
38. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., and Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
39. Hexner E.O., Serdikoff C., Jan M., Swider C.R., Robinson C., Yang S., Angeles T., Emerson S.G., Carroll M., Ruggeri B., and Dobrzanski P. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111 (2008) 5663-5671
40. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 13 (2007) 1362-1366
41. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., and Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25 (2006) 1195-1204
42. Jing N., Li Y., Xu X., Sha W., Li P., Feng L., and Tweardy D.J. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol. 22 (2003) 685-696
43. Johnson F.M., Saigal B., Talpaz M., and Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 11 (2005) 6924-6932
44. Johnson F.M., Saigal B., Tran H., and Donato N.J. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res. 13 (2007) 4233-4244
45. Kasper S., Breitenbuecher F., Hoehn Y., Heidel F., Lipka D.B., Markova B., Huber C., Kindler T., and Fischer T. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk. Res. 32 (2008) 1698-1708
46. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., Xi S., and Grandis J.R. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 13 (2002) 355-362
47. Kluge A., Dabir S., Kern J., Nethery D., Halmos B., Ma P., and Dowlati A. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int. J. Cancer 125 (2009) 1728-1734
48. Koppikar P., Lui V.W., Man D., Xi S., Chai R.L., Nelson E., Tobey A.B., and Grandis J.R. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin. Cancer Res. 14 (2008) 7682-7690
49. Kremer J.M., Bloom B.J., Breedveld F.C., Coombs J.H., Fletcher M.P., Gruben D., Krishnaswami S., Burgos-Vargas R., Wilkinson B., Zerbini C.A., and Zwillich S.H. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60 (2009) 1895-1905
50. Lai S.Y., Childs E.E., Xi S., Coppelli F.M., Gooding W.E., Wells A., Ferris R.L., and Grandis J.R. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24 (2005) 4442-4449
51. Leaman D.W., Pisharody S., Flickinger T.W., Commane M.A., Schlessinger J., Kerr I.M., Levy D.E., and Stark G.R. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell Biol. 16 (1996) 369-375
52. Lee F.Y., Lombardo L., Camuso A., Castaneda S., Fager K., Flefleh C., Inigo I., Johnson K., Kan D., Luo R., McGlinchey K., Pang S., Peterson R., Wen M., Wild R., Fairchild C., Wong T., Borzilleri R., and Kramer R. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proceedings of the American Association of Cancer Research. Anaheim, CA (2005) 675
53. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., and Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 (2009) 283-293
54. Lee T.L., Yeh J., Van Waes C., and Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol. Cancer Ther. 5 (2006) 8-19
55. Leong P.L., Andrews G.A., Johnson D.E., Dyer K.F., Xi S., Mai J.C., Robbins P.D., Gadiparthi S., Burke N.A., Watkins S.F., and Grandis J.R. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4138-4143
56. Leong P.L., Xi S., Drenning S.D., Dyer K.F., Wentzel A.L., Lerner E.C., Smithgall T.E., and Grandis J.R. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 21 18 (2002) 2846-2853
57. Le Tourneau C., Vidal L., and Siu L.L. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist. Update 11 (2008) 99-109
58. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23 (2005) 5960-5972
59. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., Jones-Bolin S., Ruggeri B., Dionne C., and Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 (2002) 3885-3891
60. Liby K., Voong N., Williams C.R., Risingsong R., Royce D.B., Honda T., Gribble G.W., Sporn M.B., and Letterio J.J. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 12 (2006) 4288-4293
61. Limnander A., and Rothman P.B. Abl oncogene bypasses normal regulation of Jak/STAT activation. Cell Cycle 3 12 (2004) 1486-1488
62. Lipka D.B., Hoffmann L.S., Heidel F., Markova B., Blum M.C., Breitenbuecher F., Kasper S., Kindler T., Levine R.L., Huber C., and Fischer T. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol. Cancer Ther. 7 (2008) 1176-1184
63. Liu J., and Kern J.A. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am. J. Respir. Cell Mol. Biol. 27 3 (2002) 306-313
64. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., and Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7 (2005) 575-589
65. LoPiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Update 11 (2008) 32-50
66. Lui V.W., Boehm A.L., Koppikar P., Leeman R.J., Johnson D., Ogagan M., Childs E., Freilino M., and Grandis J.R. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3 the role of STAT1. Mol. Pharmacol. 71 (2007) 1435-1443
67. Luo H., Hanratty W.P., and Dearolf C.R. An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 14 (1995) 1412-1420
68. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
69. Lyons J., Curry J., Mallet K., Miller D., Reule M., Sevears L., Tisi D., and Wallis N. JAK2 and T315I Abl activity of clinical candidate, AT9283. AACR Meeting Abstracts 2007 (2007) 5747
70. Mesa R.A., and Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin. Emerg. Drugs 14 3 (2009) 471-479
71. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., and Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009) 947-957
72. Morishita R., Aoki M., and Ogihara T. Does gene therapy become pharmacotherapy?. Exp. Physiol. 90 (2005) 307-313
73. Moriyama I., Ishihara S., Rumi M.A., Aziz M.D., Mishima Y., Oshima N., Kadota C., Kadowaki Y., Amano Y., and Kinoshita Y. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab. Invest. 88 (2008) 652-663
74. Nagel-Wolfrum K., Buerger C., Wittig I., Butz K., Hoppe-Seyler F., and Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. 2 (2004) 170-182
75. Nagpal J.K., Mishra R., and Das B.R. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 94 (2002) 2393-2400
76. Niu G., Wright K.L., Ma Y., Wright G.M., Huang M., Irby R., Briggs J., Karras J., Cress W.D., Pardoll D., Jove R., Chen J., and Yu H. Role of Stat3 in regulating p53 expression and function. Mol. Cell Biol. 25 (2005) 7432-7440
77. O'Sullivan L.A., Liongue C., Lewis R.S., Stephenson S.E., and Ward A.C. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol. Immunol. 44 (2007) 2497-2506
78. Ogata Y., Osaki T., Naka T., Iwahori K., Furukawa M., Nagatomo I., Kijima T., Kumagai T., Yoshida M., Tachibana I., and Kawase I. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 8 (2006) 817-825
79. Olayioye M.A., Beuvink I., Horsch K., Daly J.M., and Hynes N.E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 274 (1999) 17209-17218
80. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22 (2008) 23-30
81. Pardanani A., Lasho T., Smith G., Burns C.J., Fantino E., and Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23 (2009) 1441-1445
82. Pardanani D., Gotlib J., Jamieson C., Cortes J., Talpaz M., Stone R., Silverman M., Shorr J., Gilliland D.G., and Tefferi A. TG101348, A JAK2-selective inhibitor, is well tolerated in patients with myelofibrosis and shows substantial therapeutic activity accompanied by a reduction in JAK2V617F allele burden. 14th Annual Meeting of the European-Hematology-Association. Berlin, Germany (2009) 1088
83. Paukku K., and Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 15 6 (2004) 435-455
84. Pfeiffer M., Hartmann T.N., Leick M., Catusse J., Schmitt-Graeff A., and Burger M. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br. J. Cancer 100 (2009) 1949-1956
85. Reddy E.P., Korapati A., Chaturvedi P., and Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19 (2000) 2532-2547
86. Ren Z., Cabell L.A., Schaefer T.S., and McMurray J.S. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. 13 (2003) 633-636
87. Ruchatz H., Coluccia A.M., Stano P., Marchesi E., and Gambacorti-Passerini C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp. Hematol. 31 (2003) 309-315
88. Ruff-Jamison S., Chen K., and Cohen S. Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 92 10 (1995) 4215-4218
89. Ruff-Jamison S., Zhong Z., Wen Z., Chen K., Darnell Jr. J.E., and Cohen S. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem. 269 35 (1994) 21933-21935
90. Sanchez-Ceja S.G., Reyes-Maldonado E., Vazquez-Manriquez M.E., Lopez-Luna J.J., Belmont A., and Gutierrez-Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 54 (2006) 163-168
91. Santos F.P.S., Kantarjian H., Jain N., Thomas D., Garcia-Manero G., Cortes J., and Verstovsek S. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post-Polycythemia Vera/essential thrombocythemia myelofibrosis. 14th Annual Meeting of the European-Hematology-Association. Berlin, Germany (2009) 1087
92. Schaefer T.S., Sanders L.K., Park O.K., and Nathans D. Functional differences between Stat3alpha and Stat3beta. Mol. Cell. Biol. 17 (1997) 5307-5316
93. Schust J., Sperl B., Hollis A., Mayer T.U., and Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13 (2006) 1235-1242
94. Sen B., Saigal B., Parikh N., Gallick G., and Johnson F.M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 69 5 (2009) 1958-1965
95. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H.R., Yip M.L., Jove R., McLaughlin M.M., Lawrence N.J., Sebti S.M., and Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 7391-7396
96. Siddiquee K.A., Gunning P.T., Glenn M., Katt W.P., Zhang S., Schrock C., Sebti S.M., Jove R., Hamilton A.D., and Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2 (2007) 787-798
97. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., Murphy K.M., Dauses T., Allebach J., and Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
98. Son G., Iimuro Y., Seki E., Hirano T., Kaneda Y., and Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007) G631-G639
99. Song H., Wang R., Wang S., and Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4700-4705
100. Song J.I., and Grandis J.R. STAT signaling in head and neck cancer. Oncogene 19 21 (2000) 2489-2495
101. Song L., Turkson J., Karras J.G., Jove R., and Haura E.B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22 (2003) 4150-4165
102. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
103. Sriuranpong V., Park J.I., Amornphimoltham P., Patel V., Nelkin B.D., and Gutkind J.S. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 63 (2003) 2948-2956
104. Sun M., Behrens C., Feng L., Ozburn N., Tang X., Yin G., Komaki R., Varella-Garcia M., Hong W.K., Aldape K.D., and Wistuba I.I. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin. Cancer Res. 15 (2009) 4829-4837
105. Tan S.H., and Nevalainen M.T. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr. Relat. Cancer 15 2 (2008) 367-390
106. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematol. Am. Soc. Hematol. Educ. Program (2006) 240-245
107. Timofeeva O.A., Gaponenko V., Lockett S.J., Tarasov S.G., Jiang S., Michejda C.J., Perantoni A.O., and Tarasova N.I. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol. 2 (2007) 799-809
108. Tomita N., Azuma H., Kaneda Y., Ogihara T., and Morishita R. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases. Curr. Drug Targets 4 (2003) 339-346
109. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., Haura E., Sebti S., Hamilton A.D., and Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3 (2004) 261-269
110. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., Laudano A., Sebti S., Hamilton A.D., and Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276 (2001) 45443-45455
111. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., and Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280 (2005) 32979-32988
112. Turkson J., Zhang S., Palmer J., Kay H., Stanko J., Mora L.B., Sebti S., Yu H., and Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3 (2004) 1533-1542
113. van Gurp E., Weimar W., Gaston R., Brennan D., Mendez R., Pirsch J., Swan S., Pescovitz M.D., Ni G., Wang C., Krishnaswami S., Chow V., and Chan G. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8 (2008) 1711-1718
114. Verstovsek S., Kantarjian H., Pardanani A., Thomas D., Cortes J., Mesa R., Redman J., Staschen C.-M., Fridman J., Vaddi K., and Tefferi A. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). ASH Annu. Meeting Abstracts 110 (2007) 558
115. Verstovsek S., Kantarjian H.M., Pardanani A., Thomas D.A., Cortes J.E., Mesa R., Hogan W., Redman J., Levy R., Vaddi K., and Tefferi A. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). ASCO Meeting Abstracts 26 (2008) 7004
116. Verstovsek S., Kantarjian H.M., Pardanani A.D., Thomas D., Cortes J., Mesa R.A., Hogan W.J., Redman J.R., Erickson-Viitanen S., Levy R., Vaddi K., Bradley E., Fridman J., and Tefferi A. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF). ASH Annu. Meeting Abstracts 112 (2008) 1762
117. Verstovsek S., Pardanani A.D., Shah N.P., Sokol L., Wadleigh M., Gilliland D.G., List A.F., Tefferi A., Kantarjian H.M., Bui L.A., and Clary D.O. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. ASH Annu. Meeting Abstracts 110 (2007) 553
118. Verstovsek S., Tefferi A., Kornblau S., Thomas D., Cortes J., Ravandi-Kashani F., Garcia-Manero G., and Kantarjian H. Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis. ASH Annu. Meeting Abstracts 110 (2007) 3543
119. Weerasinghe P., Garcia G.E., Zhu Q., Yuan P., Feng L., Mao L., and Jing N. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31 (2007) 129-136
120. Weidler M., Rether J., Anke T., and Erkel G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett. 484 (2000) 1-6
121. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., Mak C.C., Noronha G., Martin M., Ko Y.D., Lee B.H., Soll R.M., Tefferi A., Hood J.D., and Gilliland D.G. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13 (2008) 311-320
122. Xi S., Gooding W.E., and Grandis J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24 (2005) 970-979
123. Xi S., Zhang Q., Dyer K.F., Lerner E.C., Smithgall T.E., Gooding W.E., Kamens J., and Grandis J.R. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. 278 34 (2003) 31574-31583
124. Xi S., Zhang Q., Gooding W.E., Smithgall T.E., and Grandis J.R. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63 (2003) 6763-6771
125. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., and Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 (2004) 3550-3560
126. Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H., Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T., and Fujisawa T. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol. Immunother. 53 (2004) 786-792
127. Yanagawa H., Sone S., Takahashi Y., Haku T., Yano S., Shinohara T., and Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br. J. Cancer 71 (1995) 1095-1098
128. Yang J., and Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res. 18 4 (2008) 443-451
129. Yeh H.H., Lai W.W., Chen H.H., Liu H.S., and Su W.C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25 (2006) 4300-4309
130. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., and Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 (1995) 81-83
131. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4 2 (2004) 97-105
132. Zhu Q., and Jing N. Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3. J. Comput. Aided Mol. Des. 21 (2007) 641-648